Coloplast delivers 2% organic growth in Q2 as well as an EBIT margin of 33% and raises full-year underlying EBIT margin guidance from 31-32% to 32-33%

.
The company reported 2% organic growth in Q2. Reported revenue in DKK was down by 1% to DKK 4,753 million, impacted by the depreciation of the USD and a number of Emerging markets currencies
against DKK. The EBIT margin was 33% before special items against 32% last year, which reflects continued strong cost control during the COVID-19 pandemic as well as sustained investments in growth
opportunities and innovation. EBIT was impacted by a further DKK 200m provision for costs related to the existing lawsuits in the US alleging injury resulting from the use of transvaginal surgical
mesh products.
In the first six months of the financial year, organic growth was 4% and the EBIT margin was 33% before special items.

Related Keywords

China ,Germany ,Hungary ,France ,Kristian Villumsen ,Ellen Bjurgert ,Corporate Communications ,Vizient Inc ,Men Health ,Emerging Markets ,Wound Care ,Interventional Urology ,Chronic Care ,Ostomy Care ,Continence Care ,Biatain Fiber ,Coloplast Sustainability ,Sustainable Growth ,Media Relations Manager ,சீனா ,ஜெர்மனி ,பசி ,பிரான்ஸ் ,பெருநிறுவன தகவல்தொடர்புகள் ,ஆண்கள் ஆரோக்கியம் ,வளர்ந்து வருகிறது சந்தைகள் ,காயம் பராமரிப்பு ,தலையீடு சிறுநீரகம் ,நாள்பட்ட பராமரிப்பு ,ஒஸ்டோமி பராமரிப்பு ,கண்டம் பராமரிப்பு ,நிலையான வளர்ச்சி ,மீடியா உறவுகள் மேலாளர் ,